rhNGF New Lyo Formulation, OXYBUPROCAINE , SODIUM CHLORIDE , rhNGF New Lyo Formulation, The placebo consists of a lyophilized product packaged in 2R siliconized glass class I vials closed with a stopper and a flip off cap and administered after reconstitution with 2mL of diluent contained into a 2R glass class I vials closed with a stopper and a flip off cap. The diluent consists of DMSO, Sesame Extract 98%, Kollifor HS 0.15%, Sodium Chloride, Water For Injection. The product is reconstituted using an ada

Quick answer

rhNGF New Lyo Formulation, OXYBUPROCAINE , SODIUM CHLORIDE , rhNGF New Lyo Formulation, The placebo consists of a lyophilized product packaged in 2R siliconized glass class I vials closed with a stopper and a flip off cap and administered after reconstitution with 2mL of diluent contained into a 2R glass class I vials closed with a stopper and a flip off cap. The diluent consists of DMSO, Sesame Extract 98%, Kollifor HS 0.15%, Sodium Chloride, Water For Injection. The product is reconstituted using an ada for Dry Eye is a Phase 2 program (small_molecule) at Dompe' Farmaceutici S.p.A. with 1 ClinicalTrials.gov record(s).